Mechanisms of modulation of ferroptosis and its role in central
nervous system
diseases
Qingyun Tan, Yuying Fang, and Qiong Gu*
Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun
Yat-sen University, Guangzhou 510006, People’s Republic of China
*Corresponding author: Qiong Gu (QG) email:guqiong@mail.sysu.edu.cn;
Word count: Text 6522 Abstract 84 Tables 1 Figures
4
ABSTRACT
Ferroptosis is a new form of programmed cell death characterized by
intracellular iron-dependent accumulation of lipid peroxide and
primarily associated with iron metabolism, glutathione-dependent
pathway, and Coenzyme
Q10-dependent pathway. Recent studies demonstrate that
ferroptosis is associated with central nervous system (CNS) diseases,
such as stroke, Parkinson’s disease, Alzheimer’s disease, and
Huntington’s disease. This review summarizes the key regulatory
mechanisms of modulation of ferroptosis and its role in CNS diseases.
These updates may provide novel perspective for the development of
therapeutical agents against CNS diseases.
KEYWORDS
Ferroptosis, Lipid metabolism, Iron metabolism, Glutathione peroxidase
4, Coenzyme Q10, Central nervous system diseases
ABBREVIATIONS
ROS, reactive oxygen species;
DFO, deferoxamine;
PUFA, polyunsaturated fatty acid;
PL, phospholipid;
RPL8 , ribosomal protein L8;
IREB2 , iron response element binding protein 2;
ATP5G3 , ATP synthase F0 complex subunit C3;
CS , citrate synthase;
TTC35 , tetratricopeptide repeat domain 35;
ACSF2 , acyl-CoA synthetase family member 2;
HSPB1, heat shock protein β-1;
PTGS2 , prostaglandin-endoperoxide synthase 2;
Fer-1, ferrostatin-1;
CQ, chloroquine;
CNS, central nervous system;
LOOH, lipid hydroperoxide;
CoQ10, coenzyme Q10;
4-HNE, 4-hydroxy-2-nonenal;
MDA, malondialdehyde;
SFA, saturated fatty acid;
MUFA, monounsaturated fatty acid;
AA, arachidonic acid;
AdA, adrenic acid;
PE, phosphatidylethanolamine;
ACSL4, acyl-CoA synthetase long-chain family member 4;
LPCAT3, lysophosphatidylcholine acyltransferase 3;
TZD, thiazolidinedione;
TRO, troglitazone;
PIO, pioglitazone;
ROSI, rosiglitazone;
LOX, lipoxygenase;
L•, pentadienyl radical;
•OH, hydroxyl radicals;
LO•, alkoxy groups;
HO2•, hydroperoxyl radicals;
LOO•, peroxy radical;
RTA, radical trapping antioxidant;
Lip-1, liproxstatin-1;
Tf, transferrin;
TfR, transferrin receptor;
DMT1, divalent metal transporter 1;
LIP, labile iron pool;
FT, ferritin;
FTH1, ferritin heavy chain 1;
FTL, ferritin light chain;
NCOA4, nuclear receptor coactivator 4;
FPN, ferroportin;
GPX4, glutathione peroxidase 4;
Se, selenium;
GSH, glutathione;
L-OH, lipid alcohol;
RSL3, Ras-selective lethal 3;
Sec, selenocysteine;
Glu, glutamate;
Cys, cysteine;
Gly, glycine;
BSO, buthionine sulfoximine;
GCL, glutamate-cysteine ligase;
IPP, isopentenyl pyrophosphate;
SQS, squalene synthase;
HMG-CoA, 3-hydroxy-3-methyl glutaryl-coenzyme A;
HMGCR, HMG-CoA reductase;
FSP1, ferroptosis suppressor protein 1;
NRF2, nuclear factor erythroid 2-related factor 2;
TXNRD1, thioredoxin reductase 1;
NADK, NAD+ kinase;
NOX, NADPH oxidase;
DPI, diphenylene iodonium;
TCA cycle, ricarboxylic acid cycle;
Keap1, Kelch-like ECH-associated protein;
NQO1 , quinone oxidoreductase-1;
HO1 , heme oxygenase-1;
ARF, auxin response factor;
FOCAD, Focadhesin;
FAK, focal adhesion kinase;
OHSC, organotypic hippocampal slice culture;
PD, Parkinson’s disease;
AD, Alzheimer’s disease;
HD, Huntington’s disease;
ICH, intracerebral hemorrhage;
MCAO, middle cerebral artery occlusion;
Hb, hemoglobin;
SNpc, substantia nigra pars compacta;
FAC, ferric ammonium citrate;
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
Aβ, amyloid-β;
NFT, neurofibrillary tangle;
HP, hippocampi;
FC, frontal cortices;
CDDO, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid;
ARE, antioxidant response element.
1. INTRODUCTION
From organisms to cells, death is the common destiny of life.
Conventional cell death removes damaged or harmful cells from organisms.
Therefore, cell death is essential for the homeostasis of life. When
cell death is over-activated, the body can suffer from many pathological
conditions, such as nervous system diseases. Thus, understanding the
process of cell death helps to intervene in cell death or survival and
develop therapeutical solutions to treat associated diseases.
The major forms of cell deaths are divided into apoptosis, autophagy,
and necrosis. Recently, morphological and biochemical criteria have been
generated to articulate cell death and mechanisms. New cell death forms
are discovered from time to time, such as pyroptosis (Fink et al., 2005)
and ferroptosis (Dixon et al., 2012).
In 2012, it was (Dixon et al., 2012) reported that erastin, a
small-molecule inducer, induced RAS -mutated tumor cell death by
overwhelming lipid peroxidation that produced lipid reactive oxygen
species (ROS). This cell death form depends on iron rather than other
metals, and can be suppressed by iron chelator deferoxamine (DFO).
Therefore, such cell death was termed as ”ferroptosis” by Dixon and
co-workers. Since then, ferroptosis has drawn a great attention. It was
found vital to many pathophysiological conditions, such as nervous
system diseases (Derry et al., 2020), ischemia/reperfusion injury (Guan
et al., 2019), tumor (Shin et al., 2020) and acute kidney injury (Ma et
al., 2020).
Based on the morphological, biochemical, and genetic characteristics,
ferroptosis is distinct from other forms of cell death. Ferroptotic
cells have smaller mitochondria with reduced crest, condensed membrane
density and ruptured outer membranes. The cells are usually rounded up
but lack of rupture and blebbing on the plasma membranes, which are the
features in apoptotic cells (Xie et al., 2016). The main biochemical
characteristic of ferroptosis is iron-dependent over-oxidation of
polyunsaturated fatty acids (PUFAs)-containing phospholipids (PLs) on
cell membranes. Apoptosis has long benefited from the detection of the
cleaved caspase-3. However, it is unclear what are the biomarkers
(either transcriptional up-regulation or, post-translational
modification of specific cell death effectors or, pore-forming proteins)
required for the final execution of ferroptosis. Initially, Dixon and
colleagues (Dixon et al., 2012) found that the expression of many genes
changed in erastin-induced ferroptosis, including ribosomal protein L8
(RPL8 ), iron response element binding protein 2 (IREB2 ),
ATP synthase F0 complex subunit C3 (ATP5G3 ), citrate synthase
(CS ), tetratricopeptide repeat domain 35 (TTC35 ) and
acyl-CoA synthetase family member 2 (ACSF2 ). Many genes involved
in the regulation of apoptosis and other non-apoptotic cell death are
not altered when ferroptosis happened. Subsequently, more genes are
being found to be associated with ferroptosis, such as heat shock
protein β-1 (HSPB1 ) (Sun et al., 2015),
prostaglandin-endoperoxide synthase 2 (PTGS2 ) (Yang et al., 2014)
and p53 (Jiang et al., 2015). Importantly, the expression ofPTGS2 was found to be significantly upregulated in ferroptosis
without changing ferroptosis process (Yang et al., 2014). Thus, this
gene expression is regarded as a biomarker of ferroptosis.
It is confirmed that ferroptosis depends on the level of lipid ROS.
Ferroptosis inhibitors, such as ferrostatin-1(Fer-1) and DFO, prevent
cell death by decreasing the lipid ROS. On the other hand, apoptosis
inhibitors (e.g., Z-VAD-FMK), necrosis inhibitors (e.g., necrostain-1)
and autophagy inhibitors (e.g., chloroquine) cannot suppress
ferroptosis.
In this review, we summarize the mechanisms of modulation of ferroptosis
and its role in central nervous system (CNS) diseases, and propose the
possible strategies for finding new ferroptosis regulators.
2. THE KEY REGULATORY MECHANISMS OF
FERROPTOSIS
Ferroptosis is intracellular excessive lipid peroxidation and the
metabolic disorders of its product lipid hydroperoxides (LOOHs)per se (Figure 1A). Iron catalyzes LOOHs over-production that
destroys the intracellular redox balance and triggers cell death.
Therefore, LOOHs are key to ferroptosis. Suppressing LOOH level can stop
ferroptosis. Lipid peroxidation and metabolic disorders of intracellular
LOOHs are mainly related to iron metabolism (Figure 1B), glutathione
(GSH)-dependent pathway (Figure 1C) and Coenzyme Q10(CoQ10)-dependent pathway (Figure 1D). The detailed
ferroptosis mechanisms are still to be articulated.
There are several hypotheses on the mechanisms: (1) Lipid peroxidation
and ROS over-production destroy cell membrane integrity through damaging
and perforating the cell membranes (Agmon et al., 2018); (2) LOOHs are
decomposed into toxic aldehydes, such as 4-hydroxy-2-nonenal (4-HNE) and
malondialdehyde (MDA), which crosslink and dysfunction the proteins
required for cell viability, result in cell death (Angeli et al., 2017;
Zhong et al., 2015).
2.1 Lipid metabolism
Compared with saturated fatty acids (SFAs) and monounsaturated fatty
acids (MUFAs), PUFAs are easier to be oxidized. This is because the
double bond near the bis -allyl methylene group in PUFAs can
weaken the hydrogen bonding energy of the methylene group, resulting in
its sensitivity to dehydrogenation and subsequent oxygenation (Else,
2017). A recent study demonstrated that, when containing the two types
of PUFAs arachidonic acid (AA) and adrenic acid (AdA), the PLs
especially phosphatidylethanolamines (PEs) on the cell membranes, are
more susceptible to be oxidized. This can lead ferroptosis eventually
(Kagan et al., 2017).
Lipid peroxidation process consists of several steps, (1) in
intracellular environment, acyl-CoA synthetase long-chain family member
4 (ACSL4) converts free AA and AdA to AA-CoA and AdA-CoA, (2), AA-CoA
and AdA-CoA are then inserted to PLs by esterification reaction under
the catalysis of lysophosphatidylcholine acyltransferase 3 (LPCAT3)
(Magtanong et al., 2018). Consequently, easily oxidized membrane PLs are
synthesized, which are required for the lethal lipid peroxidation and
ferroptosis.
Therefore, at least ACSL4 and LPCAT3 are essential for modulating
ferroptosis. The ACSL4 specific inhibitors thiazolidinediones (TZDs)
include troglitazone (TRO), pioglitazone (PIO) and rosiglitazone (ROSI)
(Figure 2A). They were reported to suppress ferroptosis in mouse
embryonic fibroblasts (Doll et al., 2017). Knockdown of Lpcat3 could
also make mouse lung epithelial cells and embryonic cells more resistant
to ferroptosis (Kagan et al., 2017). When ACSL4 or LPCAT3 are inhibited,
the available substrates of lipid peroxidation are reduced and the lipid
peroxidation is suppressed. ACSL4 and LPCAT3 are promising targets
against ferroptosis or other peroxidation related diseases.
Lipoxygenases (LOXs) are iron-containing enzymes for cell membrane PLs
oxidation, which are non-heme dioxygenases that catalyze the double
oxygenation reaction of PUFAs. Different subtypes of LOXs catalyze the
dioxygenation of PUFAs at different positions. Baicalein, a naturel
bioactive compound, was reported to inhibit ferroptosis by suppressing
12/15-LOX (Li et al., 2019).
The first step of LOXs catalysis is to abstract an unstable hydrogen
from the bis -allyl position at a PUFA to form a pentadienyl
radical (L•) (Kuhn et al., 2015). This step can also be accomplished by
an auto-oxidation reaction independent of LOXs. Highly reactive
substances such as hydroxyl radicals (•OH), alkoxy groups (LO•) and
hydroperoxyl radicals (HO2•) can take a hydrogen atom
from the bis -allyl position of a PUFA (Angeli et al., 2017).
Subsequently, molecular oxygen is added to the carbon-centered radicals
to yield a peroxy radical (LOO•). The LOO• can abstract a hydrogen atom
from an adjacent PL to generate a LOOH and a new L•. As a result, this
free radical chain reaction continues to propagate and generates more
LOOHs (Yin et al., 2011). Additionally, LOOHs can be oxidized by
Fe2+: the O-O bonds are broken and yield LO•. The LO•
participates in the free radical chain reaction, destroys the adjacent
PUFAs directly, and causes cell membrane damage and ferroptosis
(Gaschler et al., 2017).
With Fe2+, Fenton reaction converts
H2O2 to •OH radicals, which propagate
free radical chain reactions (Ayala et al., 2014). Radical trapping
antioxidants (RTAs) provide electrons to neutralize free radicals
(Hassannia et al., 2019). This suppresses the propagation of lipid
peroxidation and act as ferroptosis inhibitors. Such ferroptosis
inhibitors include Fer-1 (Dixon et al., 2012), liproxstatin-1 (Lip-1)
(Angeli et al., 2014) and α-tocopherol (vitamin E) (Kajarabille et al.,
2019) (Figure 2B).
2.2 Iron metabolism
The demand for iron is a defining characteristic of ferroptosis. Since
Fe2+ catalyzes Fenton reaction, and also is an
essential component of ROS-producing enzymes such as LOXs and NADPH
oxidase, iron affects lipid peroxidation and cellular sensitivity to
ferroptosis. Increasing the content of free Fe2+ in
cells advances their sensitivity to ferroptosis. Conversely, iron
chelators (Figure 2C) and other substances that can reduce the
concentration of intracellular iron are able to inhibit ferroptosis.
Under physiological conditions, cellular iron homeostasis is regulated
through iron uptake, storage and export.
Transferrin (Tf)-mediated iron transport is the most important way of
cellular iron uptake. It can transport Fe3+ from the
place where Fe3+ is absorbed and stored to the
iron-requiring site of the body. The Tf carrying Fe3+is recognized by the transferrin receptor (TfR) on the cell membranes
and endocytosed into the cells. Fe3+ is released from
the Tf in the acidic environment of endosomes and reduced to
Fe2+ by ferrous reductase. Afterwards,
Fe2+ is transported to the cytoplasm through divalent
metal transporter 1 (DMT1) on the endosomal membranes (Ji et al., 2015).
The free Fe2+ forms a labile iron pool (LIP) and plays
its physiological or pathological roles. Inhibiting the iron uptake
could reduce the level of LIP and suppress ferroptosis. For example,
either immuno-depletion of Tf in serum or RNAi of TfR could
significantly inhibit ferroptosis in mouse embryonic fibroblasts (Gao et
al., 2015).
The excess Fe2+ in the cells would be stored in
ferritin (FT) to maintain the content of iron under normal physiological
conditions. FT is a hollow globular protein shell composed of two types
of subunits: ferritin heavy chain 1 (FTH1) and ferritin light chain
(FTL) (Harrison et al., 1996). Each FT can store about 4500
Fe3+ in the form of
Fe2O3·nH2O (Islam et
al., 1989). Oncogene-RAS -harboring cancer cells are more
sensitive to ferroptosis, partly because RAS can down-regulate
the expression of FTH1 and FTL, increasing intracellular LIP (Yang et
al., 2008). Recent studies indicated that nuclear receptor coactivator 4
(NCOA4)-mediated ferritinophagy played a crucial role in the regulation
of iron levels. When available iron in cells is scarce, NCOA4 would
recognize and bind to FTH1, and then recruit FT to autophagosomes. With
the formation of autolysosomes, FT complexes enter lysosomes and are
degraded, subsequently Fe3+ stored in these complexes
would be released and supply the LIP. This process is also necessary for
the execution of ferroptosis. Silencing the expression of NCOA4 by RNAi
knockdown significantly inhibited ferritinophagy, thereby suppressing
ferroptosis in mouse embryonic fibroblasts (Gao et al., 2016).
In addition, excess cellular Fe2+ can also be exported
through ferroportin (FPN) on the cell membranes, which is the only known
vertebrate iron efflux pump (Bogdan et al., 2016). It was reported that
knockdown of Fpn in neuroblastoma cells could increase the
accumulation of iron-dependent lipid ROS, and thereby accelerate
erastin-induced ferroptosis (Geng et al., 2018).
2.3 GSH-dependent pathway
Glutathione peroxidase 4 (GPX4) is a selenium (Se)-containing enzyme,
which plays a central role in the reduction of lipid ROS production.
With consumption of two GSH molecules, GPX4 could reduce toxic LOOHs to
non-toxic lipid alcohols (L-OHs). However, when GPX4 is deficient or
inactive, LOOHs will accumulate to a high level, leading to catastrophic
membrane damage. It is currently believed that inhibiting GPX4 by direct
or indirect ways is the key to induce ferroptosis.
The ways to inhibit GPX4 directly mainly include covalently binding GPX4
and suppressing its expression. The compound Ras-selective lethal 3
(RSL3, Figure 2D), which can covalently bind to the selenocysteine (Sec)
at the active site of GPX4 and inhibit its activity, is a highly
effective ferroptosis inducer (Dixon et al., 2012). Knockout ofGpx4 can promote ferroptosis in mouse embryonic fibroblasts,
while overexpression of Gpx4 made cells more resistant to
RSL3-induced ferroptosis (Yang et al., 2014).
Inhibiting GPX4 indirectly mainly involves inhibition of its cofactor
GSH production. GSH is synthesized from three amino acids: glutamate
(Glu), cysteine (Cys) and glycine (Gly). Among them, the amount of Cys
is usually the least in cells, so it is considered to be the key factor
limiting the de novo synthesis of GSH. Cys exists in its oxidized
form cystine outside the cells. Through cystine/Glu antiporter
(system\(\ X_{c}^{-}\)) on the cell membranes, an extracellular cystine
is transported into cells and meanwhile an intracellular Glu is
exported. The system \(X_{c}^{-}\) is a disulfide-link heterodimer
consisting of SLC7A11 (xCT) and regulatory subunit SLC3A2 (4F2hc and
CD98hc) (Sato et al., 1999). This transport process does not depend on
ATP but is driven by the difference in the concentrations of Glu or
cystine on both sides of the membranes. Although Cys can be generated
via the transsulfuration pathway in some cell types, in many other cell
types, at least in vitro , the import of cystine via
system\(\ X_{c}^{-}\ \)is significant for maintaining the levels of Cys
and GSH, and preventing ferroptosis (Magtanong et al., 2018). When this
transport is impaired,
GSH
will be depleted, making GPX4 unable to reduce LOOHs. For example,
erastin (Figure 2D), a potent inducer of ferroptosis, is a specific
inhibitor of the system\(\ X_{c}^{-}\) (Dixon et al., 2012); the
deletion of a system\(\ X_{c}^{-}\) subunit Slc7a11 in mice
induces ferroptosis and inhibits the growth of pancreatic ductal
adenocarcinoma (Badgley et al., 2020); high concentration of
extracellular Glu inhibits the import of cystine and promotes
ferroptosis, which is termed “oxidative glutamate toxicity” in neurons
or neuronal-like cells (Magtanong et al., 2018); cystine deprivation
suppresses the growth of head and neck cancer by promoting ferroptosis
(Shin et al., 2020). Additionally, inhibiting the synthesis of GSH can
also promote ferroptosis. The compound buthionine sulfoximine (BSO,
Figure 3) can induce ferroptosis in retinal pigment epithelium by
inhibiting glutamate-cysteine ligase (GCL), a rate-limiting enzyme inde novo GSH synthesis (Sun et al., 2018).
2.4 CoQ10-dependent
pathway
However, inhibiting GPX4 did not activate ferroptosis in some cells (Zou
et al., 2019), indicating that there may be pathways independent of GPX4
to regulate ferroptosis.
Researchers have found that the mevalonate pathway could also affect
ferroptosis. Isopentenyl pyrophosphate (IPP) is a direct metabolite of
mevalonate, which can be used for Sec-tRNA prenylation,
CoQ10 synthesis and cholesterol biosynthesis (Moosmann
et al., 2004). On the one hand, only the prenylated Sec-tRNA can carry
Sec to GPX4, complete the synthesis of GPX4 (Warner et al., 2000), and
then inhibit ferroptosis (Yang et al., 2016); on the other hand, the
reduced form of CoQ10(CoQ10-H2) is a potent lipophilic
antioxidant, which can capture LOO• to prevent the spread of free
radical chain reaction and inhibit the production of LOOHs, and
meanwhile the CoQ10-H2 is oxidized
(Bentinger et al., 2007). Therefore, inhibiting Sec-tRNA prenylation and
CoQ10 synthesis will disrupt GPX4 synthesis and
CoQ10-H2antioxidant activity respectively, and eventually induce ferroptosis.
For instance, FIN56 (Figure 2D) can activate squalene synthase (SQS), a
key enzyme in cholesterol biosynthesis,39 and then
suppress Sec-tRNA prenylation and CoQ10 synthesis,
finally leading to ferroptosis in human fibrosarcoma HT1080 cells
(Hassannia et al., 2019; Shimada et al., 2016b). 3-Hydroxy-3-methyl
glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR) is an important enzyme
in the mevalonate pathway. Statins, as a type of inhibitors of HMGCR,
can promote the lethality of FIN56 (Shimada et al., 2016b).
Unless maintaining in the reduced state, the oxidized
CoQ10 is unable to inhibit the spread of LOOHs. In 2019,
Doll et al. (Doll et al., 2019) and Bersuker et al. (Bersuker et al.,
2019) conducted an overexpression screen and a synthetic lethal
CRISPR-Cas9 knockout screen, respectively. Both groups revealed that
ferroptosis suppressor protein 1 (FSP1) could suppress ferroptosis when
knockout or inhibit GPX4. FSP1 is essentially a CoQ10oxidoreductase, which utilizes NAD(P)H to catalyze the reduction of
CoQ10, maintaining the availability of
CoQ10-H2. Bersuker et al. (Bersuker et
al., 2019) found that the expression level of FSP1 was positively
correlated with ferroptosis resistance in hundreds of cancer cell lines.
Besides, in tumor xenograft mice model, the growth ofGPX4 KOFSP1 KO tumors
was suppressed, while GPX4 KO tumors grew
normally. Through screening nearly 10,000 drug-like compounds, Doll et
al. (Doll et al., 2019) identified the first effective FSP1 inhibitor
iFSP1 (Figure 2D). HT1080 and mouse Pfa1 treated with iFSP1 were much
more sensitive to ferroptosis. In conclusion, by regulating the redox of
CoQ10, FSP1 acts as an essential component of the
non-mitochondrial CoQ10 antioxidant system.
FSP1-CoQ10 is also the first found pathway that is able
to compensate for the loss of GPX4 in cells.
2.5 Other factors that regulate
ferroptosis
Besides the above pathways, there are many other factors that are
involved in the regulation of ferroptosis, including Se, NADPH,
thioredoxin, transsulfuration pathway, glutaminolysis and nuclear factor
erythroid 2-related factor 2 (NRF2) (Figure 3).
Se is currently recognized as an essential micronutrient beneficial to
health. Its beneficial effects are mainly due to its incorporation into
selenoprotein in the form of Sec (Friedmann Angeli et al., 2018). Sec is
similar to cysteine, in which sulfur is replaced by Se. As mentioned
previously, Sec is an important component of GPX4. Therefore, Se
influences cellular sensitivity to ferroptosis to some extent. It was
reported that Se deprivation significantly increases oxidative stress in
cells and their susceptibility to ferroptosis (Cardoso et al., 2017).
Moreover, Ingold et al. (Ingold et al., 2018) generated mice with
targeted mutation of the active site Sec to Cys of GPX4. They found theGpx4cys/cys mouse embryonic fibroblasts were
extremely sensitive to peroxide-induced ferroptosis. In addition to
directly participating in the synthesis of selenoproteins, Se may
increase the resistance of cells to ferroptosis in indirect ways. A
study showed that Se supplement could stimulate transcriptional adaptive
program of cells to synthesize more antioxidant selenoproteins,
including GPX4 and thioredoxin reductase 1 (TXNRD1), to block
ferroptosis (Alim et al., 2019).
NADPH can also modulate ferroptosis by indirectly affecting the activity
of GPX4, due to that it is a vital reductant in the process of GSH
production. The abundance of basal NADP(H) in cells is positively
related to the resistance to ferroptosis. It was reported that knockdown
of NAD+ kinase (NADK), an enzyme that uses
NAD+ to synthesize NADP(H), was able to decrease
NADP(H) levels in HT1080 cells and make them more susceptible to
ferroptosis inducers (Shimada et al., 2016a). In addition, NADPH oxidase
(NOX) family, which is able to decrease the available level of
intracellular NADPH, was found to be upregulated in several RASmutant tumors (Kamata, 2009). The classical NOX inhibitor diphenylene
iodonium (DPI) was found to prevent erastin-induced ferroptosis inKRAS mutant Calu-1 non-small cell lung cancer cells (Dixon et
al., 2012).
Thioredoxin, a member of cellular antioxidant family (Nordberg et al.,
2001), plays an important role in suppressing ferroptosis by maintaining
and regulating the redox homeostasis. In a recent study, Llabani et al.
(Llabani et al., 2019) performed structural modification of the natural
product pleuromutilin and synthesized a series of diverse compounds.
Through phenotypic screen and biological evaluation, they discovered
that the small molecule ferroptocide could induce lipid peroxidation and
ferroptosis in some tumor cell lines. Subsequent studies identified
ferroptocide is a covalent inhibitor of thioredoxin. This group also
demonstrated that knockdown of thioredoxin led to massive generation of
general and lipid ROS in HCT 116 colon cancer cells.
As mentioned above, in some cell types, cysteine can be generated
through the transsulfuration pathway rather than system\(\ X_{c}^{-}\).
When the intracellular cysteine is insufficient, methionine will act as
a sulfur donor and undergo a series of reactions to produce cysteine,
which can be used for the synthesis of GSH. Therefore, these cells are
not sensitive to ferroptosis induced by inhibitors of
system\(\ X_{c}^{-}\). For example, Hayano et al. (Hayano et al., 2016)
found that activation of transsulfuration pathway in HT1080 cells could
increase their resistance to erastin-induced ferroptosis. Inversely,
Wang et al. (Wang et al., 2018) designed and synthesized a compound
named CH004 as an inhibitor of cystathionine β-synthase, which catalyzes
the first enzymatic reaction in the transsulfuration pathway. They found
that compound CH004 triggered ferroptosis in hepatocellular carcinoma
HepG2 cells and significantly suppressed tumor growth in a xenograft
mice model bearing H22 mouse liver tumor cells.
Glutaminolysis is the metabolism of intracellular glutamine, through
which cells use glutamine as a carbon source for the mitochondrial
tricarboxylic acid (TCA) cycle as well as a nitrogen source for the
synthesis of certain necessary substances. Gao et al. (Gao et al., 2015)
found that glutaminolysis was necessary for ferroptosis induced by
cystine deprivation: either RNAi knockdown of glutamine influx receptor
SLC1A5 or glutaminolysis inhibitor Compound 968 could inhibit cystine
deprivation-induced ferroptosis. Mechanistically, the TCA cycle and
electron transport chain in mitochondria drive this type of ferroptosis.
Inhibition of glutaminolysis could suppress the TCA cycle, the
hyperpolarization of mitochondrial membrane potential and the
accumulation of lipid ROS, eventually inhibit ferroptosis (Gao et al.,
2019). This finding also confirmed the vital role of mitochondria in
ferroptosis, which had been long-term controversial.
NRF2, a member of basic leucine zipper transcription factors, is a key
regulator of cellular antioxidant response, because its target genes
include some antioxidant proteins/enzymes genes. Sun et al. (Sun et al.,
2016) revealed the p62-Kelch-like ECH-associated protein (Keap1)-NRF2
antioxidative signaling pathway involved in the ferroptosis resistance
in hepatocellular carcinoma cells. They found that p62 -mediated
degradation of Keap1 could promote NRF2 activation. Thus, the genes
quinone oxidoreductase-1 (NQO1 ), heme oxygenase-1 (HO1 )
and FTH1 regulated by NRF2 protected the cells from ferroptosis
by modifying lipid peroxidation and iron metabolism. In addition, it was
reported that the cells with higher expression levels of auxin response
factor (ARF) were more susceptive to ferroptosis, as ARF could inhibit
the ability of NRF2 to activate its target genes, including SLC7A11
(Chen et al., 2017). Recently, a NRF2-Focadhesin (FOCAD)-focal adhesion
kinase (FAK) signaling pathway was proposed. FOCAD-FAK signaling was
able to make non-small-cell lung carcinoma cells more sensitive to
cysteine deprivation-induced ferroptosis, while NRF2 could negatively
regulate the pathway (Liu et al., 2020). These findings underlined the
role of NRF2 in ferroptosis.
3. FERROPTOSIS AND CNS
DISEASES
With the in-depth study of ferroptosis, its therapeutic potentials have
also received widespread attention. It has been widely reported that
ferroptosis inducers can potently kill tumor cells and inhibit tumor
growth in mouse xenograft tumor models, which indicates that ferroptosis
inducers are enormous potential in human cancer treatments (Hassannia et
al., 2019; Mou et al., 2019; Shi et al., 2019). For instance, Hassannia
et al. (Hassannia et al., 2018) identified withaferin A as a natural
ferroptosis inducer in neuroblastoma, which could inhibit the in
vivo growth and recurrence rate of neuroblastoma xenografts. However,
ferroptosis was also found to cause neuronal death in rat organotypic
hippocampal slice culture (OHSC) models, showing the harmful
pathological effect of ferroptosis (Dixon et al., 2012). Moreover,
neuronal cells are more susceptible to ROS toxicity owing to their
inherent more membranous fatty acids and less antioxidant enzymes, as
well as higher oxidative metabolism (Olmez et al., 2012). Increasing
evidence indicates that ferroptosis is a driver in some CNS diseases
caused by the dysfunction and death of cerebral neurons, such as stroke,
Parkinson’s disease (PD), Alzheimer’s disease (AD), and Huntington’s
disease (HD) (Figure 4, Table 1). And ferroptosis inhibitors have
exhibited great therapeutic potential for these CNS diseases and more
efforts have been made to elucidate the role of ferroptosis in the
pathogenesis of these diseases.
3.1 Stroke
In the United States, about 795,000 people experience a new or recurrent
stroke each year. Of all strokes, 87% are ischemic stroke and 10% are
intracerebral hemorrhage (ICH) stroke (Benjamin et al., 2019). Stroke
usually leads to irreparable brain damage and the patients have to
suffer from severe sequelae, such as hemiplegia, language impairment and
cognitive impairment.
Ischemic stroke is caused by occlusion or contraction of blood vessels
that restricts blood supply to certain parts of the brain. Insufficient
blood in the brain fails to provide enough oxygen and nutrients to
neurons, leading to their activation of the ischemic cascade, which is
followed by excitotoxicity, oxidative stress, blood–brain barrier
dysfunction, microvascular injury, hemostatic activation, post-ischemic
inflammation and eventual cell death. Before ferroptosis was identified,
clinical studies had found that iron and oxidative stress could promote
brain damage caused by ischemic stroke (Carbonell et al., 2007).
Nowadays, more and more evidences prove the relationship between
ischemic stroke and ferroptosis. A recent study demonstrated that in
acute ischemic stroke model of middle cerebral artery occlusion (MCAO)
rats, neuronal ferroptosis was induced by the imbalance of iron
metabolism and redox disorder (Lan et al., 2020). While the extract of
Naotaifang, a compound Chinese herbal medicine, could suppress
ferroptosis through TFR1/DMT1 and SCL7A11/GPX4 pathways, and then played
a neuroprotective role on MCAO rats (Lan et al., 2020). After cerebral
ischemia, reperfusion is the most effective treatment. However,
reperfusion will promote the production of ROS, increasing the damage
and worsening the patients’ prognosis (Olmez et al., 2012). Therefore,
reducing brain ischemia/reperfusion injury is crucial in treating
cerebral ischemia. Guan et al. (Guan et al., 2019) found that the
natural product carvacrol could inhibit ferroptosis by increasing the
expression of GPX4, thereby exerting its protective effects on cognitive
dysfunction in gerbils exposed to ischemia/reperfusion. Additionally,
Alim et al. (Alim et al., 2019) created a Tat-linked SelP Peptide, which
could greatly reduce the cerebral infarct volume caused by
ischemia/reperfusion in mice. Mechanistically, this is because the
Tat-linked SelP Peptide could block ferroptosis by driving
transcriptional response to upregulate GPX4 in neurons.
The incidence of ICH is lower than that of ischemic stroke, but its
mortality rate is higher and therapies are fewer. ICH refers to bleeding
into the brain due to rupture or leakage of blood vessels, leading to
compression of brain tissue and neuronal damage. During this process,
hemoglobin (Hb) and heme are released from the lysed erythrocytes. They
are considered as neurotoxins because they can release iron and cause
neuronal damage and death by enhancing the formation of ROS. The iron in
dead cells can also be absorbed by surrounding cells, causing even more
catastrophic consequences (Xiong et al., 2014). The iron chelating
agents DFO can effectively reduce ICH-induced neuronal damage in rats
(Okauchi et al., 2010), and the cell death caused by ICH has the
characteristics of ferroptosis in vivo and in vitro (Zille
et al., 2017), all verifying that ferroptosis is closely related to ICH
brain damage. Li et al. (Li et al., 2017) found that ferroptosis did
occur in a mouse model of ICH and contributed to neuronal death. In
addition, ferroptosis inhibitor Fer-1 can inhibit Hb-induced neuronal
death in OHSCs.
In general, inhibiting ferroptosis can be a promising strategy for the
prevention or treatments of stroke. However, no clinical trials that use
ferroptosis inhibitors have been reported to treat stroke to date.
3.2 PD
PD is the second most universal age-related neurodegenerative disease.
The clinical manifestations include resting tremor, muscle rigidity,
gait and posture disorders, which cause great pain and inconvenience to
the patients and their families. PD is characterized by the death of
dopaminergic neurons, especially those in substantia nigra pars compacta
(SNpc) and striatum. The loss of dopaminergic neurons leads to
insufficient secretion of dopamine, a pivotal neurotransmitter in the
brain. Thus, the nerve conduction is blocked, leading to the symptoms of
dyskinesia. Currently, dopamine-based therapies such as levodopa are
used in clinic to relieve the motor symptoms in early PD. However, these
treatments have no effect on the disease progression. Therefore, it is
urgent to develop drugs that can slow or prevent the death of
dopaminergic neurons in the brain.
The iron accumulation found on SNpc is one of the characteristics of PD
patients, suggesting the link between iron and PD (Moreau et al., 2018).
As a strong reducing agent, iron can not only cause ROS production in
neurons, but also oxidize dopamine (Guiney et al., 2017). Increasing
data have proved that ferroptosis is an important pathway for the cell
death of dopaminergic neurons and the occurrence of PD. Zhang et al.
(Zhang et al., 2020) treated dopaminergic neurons MES23.5 cells with
ferric ammonium citrate (FAC) to simulate the iron overload of PD, as
FAC can upgrade ferritin levels in cells. They found ferroptosis
occurred in the early stage of cell death, which was also proved in the
PD mice. Furthermore, ferroptosis inhibitors also have a significant
therapeutic effect on the PD mouse model. In
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, a
well-established animal model of PD, Van et al. (Do Van et al., 2016)
confirmed that the ferroptosis inhibitor Fer-1 could inhibit the death
of dopaminergic neurons. Inspiringly, the results of a phase Ⅱ clinical
trial for PD patients (clinical trial NCT01539837) showed that treatment
with iron chelator deferiprone (30 mg/kg) exhibited an improvement in
motor symptoms and patients’ quality of life (Martin-Bastida et al.,
2017).
3.3 AD
AD is the most common type of irreversible dementia and a
neurodegenerative disease that often occurs in the elderly. Its
histological features are the accumulation of senile plaques composed of
amyloid-β (Aβ) and neurofibrillary tangles (NFTs) formed by
hyperphosphorylated tau protein in the memory and cognition area of the
brain (Citron, 2010). AD is caused by the degradation of memory and
cognition neurons, which may be the result of the interaction of genes
and environment. The manifestations include behavioral changes,
progressive memory loss, delusions, hallucinations and degradation in
fine motor skills. Therefore, the patients are unable to live
independently, bringing a heavy burden to the patients’ families and the
society.
Before the definition of ferroptosis, abnormal iron metabolism and lipid
peroxidation had been found to participate in the pathogenesis of AD
(Obulesu et al., 2011). Evidence indicated that AD patients showed an
excessive iron accumulation, which is more than 2 times the iron level
observed in normal brains (Lovell et al., 1998). Accumulation of iron
can not only prompt the accumulation and/or aggregation of the Aβ and
tau protein, but also induces the ROS production in the brain of AD
(Yamamoto et al., 2002). Oxidative stress is also reported to be an
important
pathological
phenomenon that begins to appear early in the course of AD (Saito et
al., 2019). When redox balance in the brain is impaired, oxidative
stress can cause serious damage leading to AD. Moreover, oxidative
stress has been reported to exacerbate AD pathology and cognitive
dysfunction (Butterfield, 1997). Besides, it was indicated that
12/15-LOX was upregulated in the brain of AD patients, which may be
related to the oxidative imbalance of AD (Pratico et al., 2004). Now
increasing evidence implicates that ferroptosis may be involved in
neuronal degeneration in AD. According to Morris water maze task,Gpx4 KO mice showed obvious defects in spatial
learning and memory function, while ferroptosis inhibitor Lip-1 could
ameliorate the neurodegeneration in these mice (Hambright et al., 2017).
Besides, a clinical measure on AD patients revealed that the level of
GSH was reduced especially in the hippocampi (HP) and frontal cortices
(FC), two vital brain regions related to the memory and cognition
functions (Mandal et al., 2015).
Therapeutically, iron chelator desferrioxamine has already been
conducted a clinical trial in AD in 1991 (Crapper McLachlan et al.,
1991). A randomized, multi-center, double-blind Phase II trial using
deferiprone for AD patients (clinical trial NCT03234686) is currently
ongoing in Australia (Rao et al., 2020). Moreover, as mentioned above,
Se can increase the resistance of cells to ferroptosis. It was reported
that Se deficiency in the human body was associated with an increased
risk of AD (Cardoso et al., 2014). However, in a phaseⅡclinical trial,
though Se could be delivered into the CNS effectively by selenate, there
were no significant effects on cognitive performance outcomes in AD
patients. Therefore, the process of ferroptosis participating in AD
needs further study, as AD may be the combination of many factors
(Cardoso et al., 2019).
3.4 HD
HD is an autosomal dominant neurodegenerative disease caused by the CAG
repeat length mutation in the huntington gene (Ross et al.,
2011). It is characterized by highly selective and severe damage to the
corpus striatum, resulting in dance-like movements, dystonia and
progressive dementia. The mutant huntington may cause oxidative
stress and neurotoxicity to the
neurons
in corpus striatum (Paul et al., 2014), which ultimately results in
neuronal dysfunction and neuronal cell death, leading to patients with
motor and cognitive impairments. However, the pathological mechanism of
HD is complicated and has not been fully elucidated yet.
Some characteristics of ferroptosis have been observed in HD patients
and experimental animal models, such as iron accumulation (Dominguez et
al., 2016), lipid oxidation (Brocardo et al., 2016), oxidative stress
(Pinho et al., 2020) and GSH redox cycle dysregulation (Ribeiro et al.,
2012). For example, in R6/2 HD mouse brain, discrete puncta formed by
iron accumulation was detected in the periplasmic cytoplasm of striated
neurons by synchrotron X-ray fluorescence analysis (Chen et al., 2013).
HD patients showed higher plasma lipid peroxidation level and lower GSH
level (Klepac et al., 2007). Consistently, Kumar et al. (Kumar et al.,
2010) found decreased GSH and GSH-S-transferase in the striatum, cortex
and hippocampus in 3-nitropropionic acid-induced HD mouse. These
phenomena imply that ferroptosis may play an important role in the
pathogenesis of HD.
Stack et al. (Stack et al., 2010) synthesized two triterpenoids derived
from 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). They could
reduce oxidative stress in the N171-82Q transgenic mouse model of HD,
and improved their rotorod performance and survival. Mechanically, the
two triterpenoids activated the NRF2/antioxidant response element (ARE)
pathway and upregulated NRF2/ARE induced genes in the brain and
peripheral tissues. Therefore, compounds targeting the NRF2/ARE pathway
show great promise for the treatment of HD. Some ferroptosis regulators
have also been found to work in HD models. For instance,
intraventricular delivery of the iron chelator DFO led to an improvement
in the motor phenotype of R6/2 HD mice (Chen et al., 2013). Skouta et
al. (Skouta et al., 2014) found that the ferroptosis inhibitor Fer-1 and
its analogues could prevent cell death in the brain slice model of HD.